Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
Fysieke inactiviteit de grootste modificeerbare risicofactor in de geneeskunde
jan 2024 | Leukemie, Lymfoom, MDS, MM, MPN